MLYS
Price:
$13.21
Market Cap:
$657.44M
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2023-02-10
Stock Exchange
NASDAQ
Ticker
MLYS
According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -55.92%. This represents a change of 288.09% compared to the average of -14.41% of the last 4 quarters.
The mean historical ROE of Mineralys Therapeutics, Inc. over the last ten years is 51.78%. The current -55.92% ROE has changed -208.01% with respect to the historical average. Over the past ten years (40 quarters), MLYS's ROE was at its highest in in the December 2021 quarter at 30.90%. The ROE was at its lowest in in the March 2022 quarter at -124.67%.
Average
51.78%
Median
70.83%
Minimum
-29.81%
Maximum
95.25%
Discovering the peaks and valleys of Mineralys Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 95.25%
Minimum Annual Increase = -152.30%
Minimum Annual ROE = -29.81%
Year | ROE | Change |
---|---|---|
2023 | -29.81% | -152.30% |
2022 | 57.01% | -32.66% |
2021 | 84.66% | -11.12% |
The current ROE of Mineralys Therapeutics, Inc. (MLYS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
37.29%
5-year avg
51.78%
10-year avg
51.78%
Mineralys Therapeutics, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Mineralys Therapeutics, Inc.'s ROE?
How is the ROE calculated for Mineralys Therapeutics, Inc. (MLYS)?
What is the highest ROE for Mineralys Therapeutics, Inc. (MLYS)?
What is the 3-year average ROE for Mineralys Therapeutics, Inc. (MLYS)?
What is the 5-year average ROE for Mineralys Therapeutics, Inc. (MLYS)?
How does the current ROE for Mineralys Therapeutics, Inc. (MLYS) compare to its historical average?